Acquired resistance to PD-L1 inhibition can rewire the interferon-regulated secretory machinery in tumor cells, altering the ...
BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...
This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement and low (TPS <10) PD-L1 tumor expression.
ABL106 has also been tested in an in vivo preclinical study using an MC38 colon cancer model that ... sites for programmed cell death ligand 1 (PD-L1) and an immune checkpoint modulator in a ...
There is growing evidence that immune-positron emission tomography (immuno-PET) can provide a real-time quantitative readout ...
PD-1/PD-L1通路可以抑制T细胞介导的肿瘤杀伤 ... 并恢复CD8 + T细胞对肿瘤细胞的杀伤作用；进一步在MC38和CT26小鼠模型中验证了体内抗肿瘤免疫治疗 ...
Agilent's PD-L1 IHC 28-8 pharmDx (Code SK005) provides clinically relevant information about PD-L1 expression - a critical biomarker for potential response to therapies containing anti-PD-1 antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback